A Boy Died a Year Ago. The Company Just Told Us.

But none of that made the information public. No press release. No conference disclosure. No proactive communication to the broader scientific community that might be running similar trials or enrolling similar patients.

The death only came to light because STAT journalists spent months digging and asking questions. On August 5, 2026, HuidaGene finally issued an update confirming everything.

Critics argue that reporting a death to a hospital ethics board is not the same as transparency. When a child dies in an experimental gene therapy trial, the scientific community needs to know, and they need to know quickly. Other researchers might be dosing patients with similar vectors at similar doses. Parents considering enrolling their children in gene therapy trials deserve to understand the risks based on the most current data.

A Pattern the Field Can't Ignore

This isn't the first time a gene therapy patient has died from an immune reaction to high-dose AAV. It's not even close.

In 2020, two patients died from liver problems linked to high-dose AAV gene therapy for X-linked myotubular myopathy, prompting the FDA to pause that trial. In 2025, Sarepta's DMD therapy Elevidys was tied to patient deaths from acute liver failure.

The through line is consistent: pumping large amounts of AAV vectors into the body can trigger catastrophic immune responses. Scientists have known this for years. The question isn't whether it can happen; it's whether we're doing enough to prevent it and, crucially, whether we're being honest when it does.

China's Oversight Gap

HuidaGene's trial was run as an investigator-initiated trial (IIT) in China. This pathway has different reporting and disclosure requirements than an FDA-regulated trial in the United States.

Under U.S. rules, sponsors must report serious and unexpected adverse reactions quickly under federal regulations (21 CFR 312.32). Deaths can trigger clinical holds, protocol changes, and public scrutiny. The FDA's gene therapy guidance even recommends 15 years of follow-up for many treatments to catch delayed problems.

China's IIT framework has historically been less transparent. Commentators say this case highlights systemic gaps in oversight and disclosure for Chinese gene therapy trials, particularly pediatric ones where the stakes are highest. China did tighten its IIT rules under Order 818, which took effect in May 2026, adding stronger suspension and reporting requirements. But those rules came too late to apply to this death.

Who Is HuidaGene?

Founded in 2018 in Shanghai, HuidaGene is a clinical-stage biotech with offices in New Jersey. The company has raised approximately $66 million across four funding rounds, with investors including WuXi AppTec and several venture firms. Its leadership includes co-founder Dr. Xuan Yao and CEO Alvin Luk, who joined in 2023.

The company's pipeline spans six clinical trials across eye diseases, neurological conditions, and neuromuscular disorders. Its proprietary platform, called HG-PRECISE, covers both DNA and RNA editing using CRISPR tools. HuidaGene has also licensed its gene-editing technology to partners in agriculture and other fields.

None of which makes the disclosure problem any less serious. If anything, a company with this many active trials has an even greater obligation to be forthcoming about safety signals.

Why This Matters Beyond One Trial

Gene therapy is one of the most promising frontiers in medicine. It offers the possibility of one-time cures for diseases that currently have no treatment. But that promise depends entirely on trust: trust from patients, trust from regulators, and trust from the scientific community.

Every time a death goes unreported for a year, that trust erodes. Every time the public learns about a fatality not from the company but from a journalist, it makes the whole field look like it has something to hide.

The tension between commercial confidentiality and public safety has haunted gene therapy for decades. The FDA actually proposed requiring public disclosure of certain gene therapy trial data back in 2001, recognizing even then that this field needed a higher bar for transparency. Twenty-five years later, we're still fighting the same battle.

HuidaGene may have followed the letter of China's reporting rules. But following the rules and doing the right thing aren't always the same thing. When a child dies in your trial, the world shouldn't have to wait a year to find out.